Publications
Detailed Information
Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Eun Ok | - |
dc.contributor.author | Park, Hee Ju | - |
dc.contributor.author | Kang, JiHee Lee | - |
dc.contributor.author | Kim, Hye-Sun | - |
dc.contributor.author | Chong, Young Hae | - |
dc.date.accessioned | 2012-07-02T05:45:12Z | - |
dc.date.available | 2012-07-02T05:45:12Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.citation | JOURNAL OF NEUROCHEMISTRY; Vol.112 6; 1477-1488 | ko_KR |
dc.identifier.issn | 0022-3042 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78088 | - |
dc.description.abstract | Published evidence has linked glutamate with the pathogenesis of Alzheimer`s disease (AD) and the up-regulation of a variety of chemokines, including monocyte chemotactic protein-1 (MCP-1)/chemokine ligand 2, with AD-associated pathological changes. In this study, we assessed the potential molecular basis for the role of glutamate in hippocampal inflammation by determining its effects on MCP-1 induction. We also attempted to identify the mechanism by which resveratrol (trans-3,5,4`-trihydroxystilbene), a polyphenolic phytostilbene, modulates the expression of MCP-1 in the glutamate-stimulated hippocampus. An ex vivo study using rat hippocampal slices demonstrated a time- and dose-dependent increase in MCP-1 release from glutamate-exposed hippocampus. This increase was accompanied by enhanced MCP-1 gene expression via the activation of the MEK/extracellular signal-regulated kinase (ERK) pathway and interleukin-1 beta (IL-1 beta) expression. The inhibition of the MEK/ERK pathway with SL327, which is capable of crossing the blood-brain barrier, nearly abolished the observed glutamate-induced effects. Furthermore, anti-IL-1 beta antibodies suppressed the glutamate-induced expression of MCP-1 mRNA and protein, whereas an isotype-matched antibody exerted only minimal effects. It is worthy of note that resveratrol, to a similar degree as SL327, down-regulated glutamate-induced IL-1 beta expression and reduced the expression of MCP-1 mRNA and protein release via the inactivation of ERK1/2. These results indicate that the activation of the MEK/ERK pathway and the consequent IL-1 beta expression are essential for glutamate-stimulated MCP-1 production in the hippocampus. Additionally, our data reveal an anti-inflammatory mechanism of resveratrol involving the inactivation of the ERK1/2 pathway in the hippocampus, which is linked principally to AD-associated cognitive dysfunction. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | Alzheimer`s disease | ko_KR |
dc.subject | interleukin-1 beta | ko_KR |
dc.subject | resveratrol | ko_KR |
dc.subject | monocyte chemoattractant protein-1 | ko_KR |
dc.subject | glutamate | ko_KR |
dc.subject | extracellular signal-regulated kinase 1 | ko_KR |
dc.subject | 2 | ko_KR |
dc.title | Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이은옥 | - |
dc.contributor.AlternativeAuthor | 박희주 | - |
dc.contributor.AlternativeAuthor | KangJiHee Lee | - |
dc.contributor.AlternativeAuthor | 김혜선 | - |
dc.contributor.AlternativeAuthor | 정영해 | - |
dc.identifier.doi | 10.1111/j.1471-4159.2009.06564.x | - |
dc.citation.journaltitle | JOURNAL OF NEUROCHEMISTRY | - |
dc.description.citedreference | Betzen C, 2009, FREE RADICAL BIO MED, V47, P1212, DOI 10.1016/j.freeradbiomed.2009.07.034 | - |
dc.description.citedreference | Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081 | - |
dc.description.citedreference | Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025 | - |
dc.description.citedreference | Sokolova A, 2009, BRAIN PATHOL, V19, P392, DOI 10.1111/j.1750-3639.2008.00188.x | - |
dc.description.citedreference | Handattu SP, 2009, NEUROBIOL DIS, V34, P525, DOI 10.1016/j.nbd.2009.03.007 | - |
dc.description.citedreference | Kuhle J, 2009, EUR J NEUROL, V16, P771, DOI 10.1111/j.1468-1331.2009.02560.x | - |
dc.description.citedreference | Katayama T, 2009, J NEUROSCI RES, V87, P1573, DOI 10.1002/jnr.21982 | - |
dc.description.citedreference | Kang OH, 2009, PHARMACOL RES, V59, P330, DOI 10.1016/j.phrs.2009.01.009 | - |
dc.description.citedreference | Penumathsa SV, 2009, CAN J PHYSIOL PHARM, V87, P275, DOI 10.1139/Y09-013 | - |
dc.description.citedreference | Vukic V, 2009, NEUROBIOL DIS, V34, P95, DOI 10.1016/j.nbd.2008.12.007 | - |
dc.description.citedreference | Park DW, 2009, EXP MOL MED, V41, P171, DOI 10.3858/emm.2009.41.3.020 | - |
dc.description.citedreference | Pallas M, 2009, CURR NEUROVASC RES, V6, P70 | - |
dc.description.citedreference | Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008 | - |
dc.description.citedreference | Madrigal JLM, 2009, J NEUROSCI, V29, P263, DOI 10.1523/JNEUROSCI.4926-08.2009 | - |
dc.description.citedreference | Shakibaei M, 2009, MOL NUTR FOOD RES, V53, P115, DOI 10.1002/mnfr.200800148 | - |
dc.description.citedreference | YOUSUF S, 2009, BRAIN RES, V250, P242 | - |
dc.description.citedreference | LIM JH, 2009, FOOD CHEM TOXICOL, V48, P47 | - |
dc.description.citedreference | de Almeida LMV, 2008, ARCH BIOCHEM BIOPHYS, V480, P27, DOI 10.1016/j.abb.2008.09.006 | - |
dc.description.citedreference | Lee JH, 2008, J NEUROCHEM, V106, P1066, DOI 10.1111/j.1471-4159.2008.05444.x | - |
dc.description.citedreference | Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005 | - |
dc.description.citedreference | Carlsson CM, 2008, J ALZHEIMERS DIS, V15, P327 | - |
dc.description.citedreference | PINEAU I, 2008, GLIA, V57, P351 | - |
dc.description.citedreference | Ates O, 2007, J CLIN NEUROSCI, V14, P256, DOI 10.1016/j.jocn.2005.12.010 | - |
dc.description.citedreference | Denker SP, 2007, J NEUROCHEM, V100, P893, DOI 10.1111/j.1471-4159.2006.04162.x | - |
dc.description.citedreference | Wang JQ, 2007, J NEUROCHEM, V100, P1, DOI 10.1111/j.1471-4159.2006.04208.x | - |
dc.description.citedreference | Cullen JP, 2007, J VASC RES, V44, P75, DOI 10.1159/000098155 | - |
dc.description.citedreference | Galimberti D, 2006, NEUROBIOL AGING, V27, P1763, DOI 10.1016/j.neurobiolaging.2005.10.007 | - |
dc.description.citedreference | Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025 | - |
dc.description.citedreference | Tanuma N, 2006, ACTA NEUROPATHOL, V112, P195, DOI 10.1007/s00401-006-0083-7 | - |
dc.description.citedreference | Chong YH, 2006, J BIOL CHEM, V281, P20315, DOI 10.1074/jbc.M601016200 | - |
dc.description.citedreference | Galimberti D, 2006, ARCH NEUROL-CHICAGO, V63, P538 | - |
dc.description.citedreference | Sastre M, 2006, INT J DEV NEUROSCI, V24, P167, DOI 10.1016/j.ijdevneu.2005.11.014 | - |
dc.description.citedreference | Henkel JS, 2006, MOL CELL NEUROSCI, V31, P427, DOI 10.1016/j.mcn.2005.10.016 | - |
dc.description.citedreference | Bellizzi MJ, 2006, J NEUROIMMUNE PHARM, V1, P20, DOI 10.1007/s11481-005-9006-y | - |
dc.description.citedreference | Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022 | - |
dc.description.citedreference | Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002 | - |
dc.description.citedreference | Holopainen IE, 2005, NEUROCHEM RES, V30, P1521, DOI 10.1007/s11064-005-8829-5 | - |
dc.description.citedreference | Francis PT, 2005, CNS SPECTRUMS, V10, P6 | - |
dc.description.citedreference | Brodmerkel CM, 2005, J IMMUNOL, V175, P5370 | - |
dc.description.citedreference | LIPTON SA, 2005, CURR ALZHEIMER RES, V2, P155 | - |
dc.description.citedreference | Chang L, 2004, ANTIVIR THER, V9, P431 | - |
dc.description.citedreference | Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688 | - |
dc.description.citedreference | Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651 | - |
dc.description.citedreference | Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960 | - |
dc.description.citedreference | Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20 | - |
dc.description.citedreference | Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074 | - |
dc.description.citedreference | Pliss L, 2002, NEUROSCI LETT, V317, P85 | - |
dc.description.citedreference | Grammas P, 2001, NEUROBIOL AGING, V22, P837 | - |
dc.description.citedreference | Baudry M, 2001, NEUROBIOL LEARN MEM, V76, P284, DOI 10.1006/nlme.2001.4023 | - |
dc.description.citedreference | Ono K, 1999, LAB INVEST, V79, P195 | - |
dc.description.citedreference | Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135 | - |
dc.description.tc | 5 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.